Boston Scien Cp Stock Price, News & Analysis

Boston Scientific Corporation (NYSE: BSX) will attend the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 8:15 a.m. PST in San Francisco, California. CEO Mike Mahoney will present alongside other key executives. Additionally, the company will host a conference call on February 1, 2023, at 8:00 a.m. EST, to discuss its fourth-quarter financial results for the period ending December 31, 2022. A news release will precede this call, providing financial highlights.

Boston Scientific Corporation (BSX) announced a partial offer to acquire up to 65% of Acotec Scientific Holdings Limited for HK$20 per share, totaling approximately US$523 million. Acotec specializes in innovative medical solutions, generating RMB 339 million in sales for the 12 months ending June 30, 2022, reflecting a 25% year-over-year growth. The acquisition aims to enhance Boston Scientific's presence in China and commercialize Acotec's products globally. While the expected impact on adjusted earnings per share is immaterial in 2023, the transaction's completion is subject to shareholder approval.

Boston Scientific has announced a definitive agreement to acquire Apollo Endosurgery for $10 per share, valuing the deal at approximately $615 million. This acquisition aims to enhance Boston Scientific's endoluminal surgery portfolio and expand its presence in the endobariatric market, a growing sector for weight management solutions. Apollo is projected to generate net sales of around $76 million in 2022, driven by its innovative endoscopic suturing systems. The transaction is expected to close in the first half of 2023, with minimal impact on adjusted earnings per share in 2023 but accretive thereafter.

Boston Scientific Corporation (NYSE:BSX) announced the initial results from the ACURATE neo2 Post Market Clinical Follow-up study. Key findings include a high procedural success rate of 98.4%, low mortality rates of 0.8% at 30 days, and minimal paravalvular leaks. The study involved 250 patients and highlighted significant safety and effectiveness of the ACURATE neo2 Aortic Valve System. Notable outcomes included a 6.5% new pacemaker implantation rate and a 0% incidence of disabling stroke. These findings bolster confidence in the valve's design improvements.

Boston Scientific (NYSE: BSX) will participate in two key investor conferences. On November 15, 2022, executives Dan Brennan and Lauren Tengler will engage in a 30-minute Q&A at the 2022 Stifel Healthcare Conference, starting at 8:00 a.m. EST. Following this, on November 30, 2022, Jeff Mirviss, Catherine Jennings, Dr. Michael Jaff, and Lauren Tengler will hold a 45-minute Q&A at the 5th Annual Evercore ISI HealthCONx Conference, also at 8:00 a.m. EST. Live webcasts for both events will be available at investors.bostonscientific.com.

Boston Scientific reported third-quarter 2022 net sales of $3.170 billion, an 8.1% increase year-over-year. GAAP net income was $174 million or $0.12 per share, down from $405 million or $0.28 per share the previous year. Adjusted EPS rose slightly to $0.43 from $0.41. Key growth segments included MedSurg and Cardiovascular, with notable expansions in Emerging Markets at 28.1%. The company is revising its full-year outlook, expecting 6.5% growth and EPS between $0.57 and $0.63.

Boston Scientific Corporation (NYSE: BSX) has scheduled a conference call for October 26, 2022, at 8:00 a.m. EDT to discuss financial results and business highlights for Q3 2022, which ended on September 30. The call will be led by CEO Mike Mahoney and CFO Dan Brennan. A press release with the financial results will be issued prior to the call. Investors can access the live webcast and replay on the company’s investor relations website.

Boston Scientific Corporation (BSX) presented results from the PROTECTED TAVR trial at TCT 2022, evaluating the SENTINEL Cerebral Protection System. The trial aimed to assess the reduction of strokes in TAVR patients. While the primary endpoint was not met, a non-significant trend showed a 21% relative risk reduction in all strokes (2.3% with SENTINEL vs. 2.9% without). Notably, there was a significant 60% reduction in disabling strokes (0.5% with SENTINEL vs. 1.3% without, P=0.02). The study involved 3,000 patients across over 50 sites, emphasizing the SENTINEL device's potential benefits in stroke prevention.

Boston Scientific (NYSE: BSX) has received FDA approval to expand the labeling for its WATCHMAN FLX Left Atrial Appendage Closure Device. The update allows for a 45-day dual anti-platelet therapy (DAPT) option as an alternative to the existing oral anticoagulation (OAC) regimen for patients with non-valvular atrial fibrillation (NVAF). This change provides physicians with more treatment flexibility based on patient needs. Clinical data, including analyses of over 8,300 patients, supports the safety and efficacy of the DAPT regimen. The device demonstrated significant advantages in clinical trials, including higher rates of complete occlusion compared to competitors.